Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

BMO Capital lowered the firm’s price target on Q32 Bio (QTTB) to $22 from $64 but keeps an Outperform rating on the shares. The company ...

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

The company announced top-line results from the SIGNAL-AA Phase IIa signal finding clinical trial evaluating bempikibart (ADX ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

Oppenheimer slashed its price target on the stock to $20 from $80, but maintained the stock at Outperform. This comes after ...

Q32 Bio Inc.’s bempikibart failed to best placebo on the primary endpoint of percent change from baseline to week 14 in the Eczema Area and Severity Index (EASI) score, sending the company’s stock ...

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.